Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

143 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea.
Yacoub A, Mascarenhas J, Kosiorek H, Prchal JT, Berenzon D, Baer MR, Ritchie E, Silver RT, Kessler C, Winton E, Finazzi MC, Rambaldi A, Vannucchi AM, Leibowitz D, Rondelli D, Arcasoy MO, Catchatourian R, Vadakara J, Rosti V, Hexner E, Kremyanskaya M, Sandy L, Tripodi J, Najfeld V, Farnoud N, Papaemmanuil E, Salama M, Singer-Weinberg R, Rampal R, Goldberg JD, Barbui T, Mesa R, Dueck AC, Hoffman R. Yacoub A, et al. Among authors: hexner e. Blood. 2019 Oct 31;134(18):1498-1509. doi: 10.1182/blood.2019000428. Blood. 2019. PMID: 31515250 Free PMC article. Clinical Trial.
A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis.
Mascarenhas J, Kosiorek H, Prchal J, Yacoub A, Berenzon D, Baer MR, Ritchie E, Silver RT, Kessler C, Winton E, Finazzi MC, Rambaldi A, Vannucchi AM, Leibowitz D, Rondelli D, Arcasoy MO, Catchatourian R, Vadakara J, Rosti V, Hexner E, Kremyanskaya M, Sandy L, Tripodi J, Najfeld V, Farnoud N, Salama ME, Weinberg RS, Rampal R, Goldberg JD, Mesa R, Dueck AC, Hoffman R. Mascarenhas J, et al. Among authors: hexner e. Leukemia. 2019 Dec;33(12):2974-2978. doi: 10.1038/s41375-019-0524-7. Epub 2019 Jul 30. Leukemia. 2019. PMID: 31363161 Free PMC article. No abstract available.
Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms.
Rampal RK, Mascarenhas JO, Kosiorek HE, Price L, Berenzon D, Hexner E, Abboud CN, Kremyanskaya M, Weinberg RS, Salama ME, Menghrajani K, Najfeld V, Sandy L, Heaney ML, Levine RL, Mesa RA, Dueck AC, Goldberg JD, Hoffman R. Rampal RK, et al. Among authors: hexner e. Blood Adv. 2018 Dec 26;2(24):3572-3580. doi: 10.1182/bloodadvances.2018019661. Blood Adv. 2018. PMID: 30563881 Free PMC article. Clinical Trial.
Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase.
Mascarenhas JO, Rampal RK, Kosiorek HE, Bhave R, Hexner E, Wang ES, Gerds A, Abboud CN, Kremyanskaya M, Berenzon D, Odenike O, Farnoud N, Krishnan A, Weinberg RS, McGovern E, Salama ME, Najfeld V, Medina-Martinez JS, Arango Ossa JE, Levine MF, Zhou Y, Sandy L, Heaney ML, Levine RL, Mesa RA, Dueck AC, Hoffman R. Mascarenhas JO, et al. Among authors: hexner e. Blood Adv. 2020 Oct 27;4(20):5246-5256. doi: 10.1182/bloodadvances.2020002119. Blood Adv. 2020. PMID: 33104796 Free PMC article. Clinical Trial.
Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT).
Mesa RA, Verstovsek S, Cervantes F, Barosi G, Reilly JT, Dupriez B, Levine R, Le Bousse-Kerdiles MC, Wadleigh M, Campbell PJ, Silver RT, Vannucchi AM, Deeg HJ, Gisslinger H, Thomas D, Odenike O, Solberg LA, Gotlib J, Hexner E, Nimer SD, Kantarjian H, Orazi A, Vardiman JW, Thiele J, Tefferi A; International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Mesa RA, et al. Among authors: hexner e. Leuk Res. 2007 Jun;31(6):737-40. doi: 10.1016/j.leukres.2006.12.002. Epub 2007 Jan 8. Leuk Res. 2007. PMID: 17210175 Review.
Phase II trial of Lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosis.
Mascarenhas J, Baer MR, Kessler C, Hexner E, Tremblay D, Price L, Sandy L, Weinberg R, Pahl H, Silverman LR, Goldberg JD, Kosiorek H, Dueck AC, Hoffman R. Mascarenhas J, et al. Among authors: hexner e. Leuk Lymphoma. 2019 May;60(5):1343-1345. doi: 10.1080/10428194.2018.1532509. Epub 2019 Jan 22. Leuk Lymphoma. 2019. PMID: 30668266 Free PMC article. Clinical Trial. No abstract available.
Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium.
Mascarenhas J, Heaney ML, Najfeld V, Hexner E, Abdel-Wahab O, Rampal R, Ravandi F, Petersen B, Roboz G, Feldman E, Podoltsev N, Douer D, Levine R, Tallman M, Hoffman R; Post-myeloproliferative neoplasm acute myeloid leukemia consortium. Mascarenhas J, et al. Among authors: hexner e. Leuk Res. 2012 Dec;36(12):1500-4. doi: 10.1016/j.leukres.2012.08.013. Epub 2012 Aug 28. Leuk Res. 2012. PMID: 22938832 Free PMC article.
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis.
Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Sun W, Sandor V, Kantarjian HM. Verstovsek S, et al. Among authors: hexner e. Br J Haematol. 2013 May;161(4):508-16. doi: 10.1111/bjh.12274. Epub 2013 Mar 11. Br J Haematol. 2013. PMID: 23480528 Free PMC article. Clinical Trial.
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.
Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner EO, Lyons RM, Raza A, Vaddi K, Sun W, Peng W, Sandor V, Kantarjian H; COMFORT-I investigators. Verstovsek S, et al. Haematologica. 2015 Apr;100(4):479-88. doi: 10.3324/haematol.2014.115840. Epub 2015 Jan 23. Haematologica. 2015. PMID: 25616577 Free PMC article.
143 results